CTKB Cytek Biosciences, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1831915 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.5%
TTM net income YoY-533.4%
TTM EPS YoY-519.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR—
Margins
Gross margin54.7%
Operating margin-21.1%
Net margin-39.1%
FCF margin-6.5%
EBITDA margin-18.2%
Returns
ROE-23.2%
ROA-17.3%
ROIC (approx.)-12.8%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets28.0%
Debt / equity0.00x
Current ratio4.46x
Interest coverage-562.56x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $201.49M | $200.45M |
| Cost of revenue | $97.03M | $89.35M |
| Gross profit | $104.46M | $111.11M |
| R&D expense | $36.47M | $39.40M |
| SG&A expense | $58.94M | $43.11M |
| Operating income | -$40.38M | -$20.52M |
| Interest expense | $474,000 | -$5.24M |
| Pretax income | -$29.84M | -$5.70M |
| Income tax | $36.70M | $320,000 |
| Net income | -$66.54M | -$6.02M |
| EBITDA | -$32.80M | -$13.31M |
| EPS (diluted) | — | — |
| Weighted avg. shares (diluted) | 127.75M | 130.61M |
| Balance sheet | ||
| Cash & equivalents | $90.85M | $98.75M |
| Receivables | $62.51M | $60.59M |
| Inventory | $48.43M | $43.89M |
| Current assets | $392.00M | $396.45M |
| PP&E, net | $18.01M | $17.96M |
| Goodwill | $16.70M | $16.66M |
| Intangibles | $16.82M | $20.13M |
| Total assets | $461.54M | $499.50M |
| Current liabilities | $77.80M | $67.66M |
| Total liabilities | $119.80M | $103.76M |
| Shareholders' equity | $341.74M | $395.74M |
| Shares outstanding | 128.55M | 129.21M |
| Cash flow statement | ||
| Operating cash flow | -$4.69M | $25.38M |
| Capital expenditure | $4.08M | $3.52M |
| Free cash flow | -$8.77M | $21.85M |
| Investing cash flow | $10.12M | -$82.97M |
| Financing cash flow | -$13.43M | -$15.82M |
| Depreciation & amortization | $7.58M | $7.21M |
| Stock-based compensation | $24.59M | $26.85M |
| Share buybacks | $15.07M | $21.61M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.